Immunotherapy for Triple-Negative Breast Cancer – OncLive
|
Immunotherapy for Triple-Negative Breast Cancer
OncLive What happens is with immunotherapy for breast cancer, because it's not a very immunogenic disease, it's really important to do it early. We saw a doubling or tripling of pathologic complete response rates in the neoadjuvant I-SPY trial. In the first … |
